Gainers & Losers
Fri Jul 18 2025 10:29:43- Wipro share price
- ₹266.902.56%
- Bajaj Finance share price
- ₹941.851.94%
- Tata Steel share price
- ₹162.501.66%
- Nestle India share price
- ₹2,472.800.98%
- Indusind Bank share price
- ₹870.950.71%
Active Stocks
Fri Jul 18 2025 10:29:34- Oil And Natural Gas Corp share price
- ₹246.351.00%
- Wipro share price
- ₹266.902.56%
- Indian Oil Corp share price
- ₹150.05-0.56%
- Axis Bank share price
- ₹1,099.10-5.24%
- Tata Steel share price
- ₹162.501.66%
Business News/Market/Market Stats/Suven Pharmaceuticals share price/ Suven Pharmaceuticals Profit Loss Annual
Suven Pharmaceuticals Profit & Loss Annual
1,071.50 -21.55 (-1.97%)Updated : 18 Jul 2025
| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Operating Expense | 899.87 | 700.00 | 821.52 | 779.69 |
| Other Net | 58.56 | 6.35 | 3.40 | 75.79 |
| Diluted Weighted Average Shares | 25.34 | 25.46 | 25.46 | 25.46 |
| Depreciation/ Amortization | 77.49 | 54.50 | 47.73 | 39.10 |
| Operating Income | 297.71 | 351.35 | 518.81 | 540.53 |
| Net Income | 264.77 | 300.28 | 411.29 | 453.80 |
| Income Availableto Com Excl Extra Ord | 264.77 | 300.28 | 411.29 | 453.80 |
| Net Income Before Taxes | 343.92 | 405.67 | 559.73 | 667.59 |
| Other Operating Expenses Total | 267.53 | 50.00 | 61.91 | 51.84 |
| Net Income After Taxes | 264.77 | 300.28 | 411.29 | 453.80 |
| Income Availableto Com Incl Extra Ord | 264.77 | 300.28 | 411.29 | 453.80 |
| Costof Revenue Total | 305.29 | 432.62 | 568.34 | 550.28 |
| Gross Profit | 892.29 | 618.73 | 771.99 | 769.94 |
| Interest Inc( Exp) Net- Non- Op Total | -12.35 | 48.10 | 37.53 | 51.47 |
| Diluted Net Income | 264.77 | 300.28 | 411.29 | 453.80 |
| Provisionfor Income Taxes | 79.15 | 105.39 | 148.44 | 213.79 |
| period Type | - | - | - | - |
| Net Income Before Extra Items | 264.77 | 300.28 | 411.29 | 453.80 |
| Total Revenue | 1,197.58 | 1,051.35 | 1,340.33 | 1,320.22 |
| period Length | 12.00 | 12.00 | 12.00 | 12.00 |
| Revenue | 1,197.58 | 1,051.35 | 1,340.33 | 1,320.22 |
| Selling/ General/ Admin Expenses Total | 249.56 | 159.66 | 134.95 | 128.12 |
| Diluted Normalized EPS | 10.45 | 11.89 | 16.16 | 17.83 |
| Diluted EPS Excluding Extra Ord Items | 10.45 | 11.80 | 16.16 | 17.83 |
| Total Adjustmentsto Net Income | - | 0.00 | - | 0.00 |
| Gain( Loss)on Saleof Assets | - | -0.14 | -0.01 | -0.20 |
| Unusual Expense( Income) | - | 3.22 | - | - |
| DPS- Common Stock Primary Issue | - | - | 1.00 | 2.00 |
| Research Development | - | - | 8.59 | 10.35 |
*All figures in crores except per share values
Suven Pharmaceuticals Quick Links
Suven Pharmaceuticals Dividend Suven Pharmaceuticals Bonus Suven Pharmaceuticals News Suven Pharmaceuticals AGM Suven Pharmaceuticals Rights Suven Pharmaceuticals Splits Suven Pharmaceuticals Board Meetings Suven Pharmaceuticals Key Metrics Suven Pharmaceuticals Shareholdings Suven Pharmaceuticals Balance Sheet Suven Pharmaceuticals Cashflow Suven Pharmaceuticals Q1 Results Suven Pharmaceuticals Q2 Results Suven Pharmaceuticals Q3 Results Suven Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
266.90+6.65(2.56%)
941.85+17.95(1.94%)
162.50+2.65(1.66%)
1,099.10-60.75 (-5.24%)
1,901.05-28.85 (-1.49%)